Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that they have been issued a second broad patent (7,138,107) by the U.S. Patent and Trademark Office (USPTO) for its invention entitled “Inhibition of olfactory neurosensory function to treat obesity and related disorders.” The patent broadly protects key aspects of Compellis’ novel obesity therapeutic strategy. Compellis has successfully demonstrated its therapeutic effect on weight gain in pre-clinical animal models and the results are published in “Pharmacology, Biochemistry and Behavior.”
“This second patent issuance significantly broadens the company’s intellectual property portfolio and is a valuable asset for its obesity therapeutic platform,” said Chris Adams, president and CEO of Compellis Pharmaceuticals. “This second patent expands the scope of the company’s invention by protecting a broad class of calcium channel antagonists to treat obesity. This includes all new and existing molecules, covering both methods and composition of matter. This second patent greatly enhances the commercial potential of Compellis’ obesity therapeutic strategy. The next step in development is completion of human testing with CP404.”
CP404 is a calcium channel blocker used in a nasal formulation to block olfactory activity and reduce food intake. Compellis has tested a series of like compounds and the effect can be seen in the overall class of calcium channel blockers. The advantage of CP404 is that because it is a small molecule, it is well-tolerated in man and is readily manufactured. Based on its prior use in humans for certain other disorders, Compellis believes some of the drawbacks typically associated with unproven compounds will not be an issue with CP404. The result is a focused clinical development process that may result in a faster time to market.
About Compellis Pharmaceuticals, Inc.
Compellis Pharmaceuticals, an early-stage biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity. The company reformulates FDA approved products and identifies proprietary delivery methods to treat broad metabolic disorders. For more information, please visit www.compellis.com.
For more information contact: Chris Adams President and CEO Compellis Pharmaceuticals, Inc. 617-957-9858 [email protected]
SOURCE: Compellis Pharmaceuticals
Comments